It has been shown that miR1013p can reduce the inflammatory response of peripheral blood mononuclear cells in SLE by inhibiting the expression of MAPK1 and blocking the NF-κB pathway (Zhao et al., 2021). This evidence concerns the gene NFKB1 and systemic lupus erythematosus.